Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18508 | 0.73 | — | — | |
| SCHEMBL2109 | 0.71 | CYP2A6 (0.50) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| SCHEMBL9496102 | 0.69 | CYP2A6 (0.89) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| SCHEMBL3138002 | 0.69 | — | — | |
| Methane SCHEMBL21489530 | 0.69 | CYP2A6 (0.89) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| Ammonia Solution, Strong SCHEMBL28776475 | 0.69 | — | — | |
| SCHEMBL21518322 | 0.69 | — | — | |
| SCHEMBL12353992 | 0.67 | CYP2A6 (0.44) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| SCHEMBL31090732 | 0.65 | ALDH1A1 (0.48) | CYP2A6ALDH1A1ALOX15MAPK1CA2 | |
| SCHEMBL68094 | 0.62 | ALDH1A1 (0.73) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| EP-2379566-A2 | GAMMA SECRETASE MODULATORS | Schering Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2379563-A1 | GAMMA SECRETASE MODULATORS | Schering Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010075204-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075203-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | CYP2A6 2025/4885ALDH1A1 2161/4885ALOX15 2567/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | CYP2A6 2025/4885ALDH1A1 2161/4885ALOX15 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.